

# Alberto Gabizon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2358217/publications.pdf>

Version: 2024-02-01

17  
papers

2,744  
citations

623574

14  
h-index

940416

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

4412  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Pharmacokinetics of Pegylated Liposomal Doxorubicin. <i>Clinical Pharmacokinetics</i> , 2003, 42, 419-436.   | 1.6 | 1,339     |
| 2  | Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 1177-1192.  | 6.6 | 434       |
| 3  | In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. <i>Clinical Cancer Research</i> , 2003, 9, 6551-9.  | 3.2 | 212       |
| 4  | Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 43-52.  | 1.1 | 105       |
| 5  | An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 695-702.   | 1.1 | 99        |
| 6  | Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1407-1416.                     | 1.7 | 61        |
| 7  | Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: Studies with human gastro-entero-pancreatic ectopic tumor models. <i>Journal of Controlled Release</i> , 2012, 160, 245-253.                              | 4.8 | 55        |
| 8  | Adoptive Immunotherapy of Epithelial Ovarian Cancer with CD8 T Cells, Potentiated by Liposomal Alendronic Acid. <i>Journal of Immunology</i> , 2014, 193, 5557-5566.   | 0.4 | 43        |
| 9  | Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer. <i>Journal of Drug Targeting</i> , 2016, 24, 878-889.   | 2.1 | 28        |
| 10 | Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil®): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues. <i>Pharmaceutical Research</i> , 2016, 33, 686-700.                          | 1.7 | 28        |
| 11 | Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 13-26.  | 6.6 | 28        |
| 12 | Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics". <i>Journal of the National Cancer Institute</i> , 2014, 106, dju321-dju321.   | 3.0 | 26        |
| 13 | Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy. <i>Molecular Pharmaceutics</i> , 2017, 14, 4339-4345. | 2.3 | 18        |
| 14 | Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. <i>Kidney International</i> , 2014, 85, 213.   | 2.6 | 12        |
| 15 | Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy. , 2021, 4, 463-484.   |     | 4         |
| 16 | A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1049-1049.                    | 0.8 | 1         |
| 17 | Next-generation sequencing (NGS) in metastatic colorectal cancer (CRC) patients (pts) in Israel.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14548-e14548.   | 0.8 | 0         |